Treatment of malignant lymphomas with methyl ester of streptonigrin (NSC 45384)


  • Shirley L. Rivers MD,

    Corresponding author
    • Veterans Administration Hospital, 1670 Clairmont Road, Atlanta, Ga. 30329
    Search for more papers by this author
    • Research Associate, Cancer Chemotherapy Research and Associate in Medicine, Emory University School of Medicine.

  • Richard M. Whittington MD,

  • Theodore J. Medrek MD

  • Picolinic acid, 5-amino-6-(6-amino-5, 8-dihydro-7-methoxy-2-quinolyl)-4-(2-hydroxy-3, 4-dimethoxyphenyl)-3-methyl-, methyl ester. The drug was obtained from the John L. Smith Memorial for Cancer Research, Chas. Pfizer and Company, Inc., Maywood, N.J., where it was produced under contract PH 43-64-50 with the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Bethesda, Md.


Forty three patients with lymphomas or chronic lymphocytic leukemia were treated with intravenous methyl ester of streptonigrin. The total dose for a single course ranged from 0.05 to 0.3 mg/kg, the optimum being 0.1 mg/kg. Thirty patients lived for at least 6 weeks and were considered evaluable. Nine objective remissions were seen in Hodgkin's disease, 5 in lymphocytic lymphoma, 2 in mycosis fungoides and 4 in chronic lymphocytic leukemia. The other 10 patients showed some evidence of favorable drug effect. Immediate toxic reactions were mainly nausea and emesis, though 3 patients had striking but reversible hypotension at the time the drug was administered. Thrombocytopenia occurred in 24 patients and leukopenia in 15 patients. Marrow suppression was generally reversible in 2 to 3 weeks.